The U.S. consented to pay $1.95 billion July 22 for approximately 600 million doses of BNT162, the speculative COVID-19 vaccine Pfizer is establishing with BioNTech. Pfizer is charging the U.S. $19.50 a dose for the first 100 million dosages.
More short articles on drug store: Trumps conference with pharma execs canceled after drug lobbies refuse to reveal upAstraZeneca to pay Emergent $174M to broaden production of COVID-19 vaccine candidateGeneric drug trade group loses quote to block California pay-to-delay law.
The drugmakers CEO, Albert Bourla, PhD, told Barrons he highly opposes the viewpoint some have that drugmakers should not earn a profit off COVID-19 vaccines and treatments.
Pfizer started stage 2/3 trials for BNT162 July 27. Dr. Bourla said the drugmaker plans to dose the bulk of this stages individuals by the end of August and submit the vaccine for FDA approval in October.
” Who is discovering the option? The personal sector discovered the service for diagnostics, and the economic sector found the solution for rehabs and is along [the] method to find more solutions for vaccines and therapeutics. How can you state something like that? Does not make good sense,” Dr. Bourla said to Barrons.
Katie Adams –
Tuesday, July 28th, 2020
Pfizer said July 28 that no developed country will pay a lower price for its COVID-19 vaccine than the U.S. for similar volume dedications..
” Who is finding the solution? How can you state something like that? Does not make sense,” Dr. Bourla said to Barrons.
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by click on this link.